In summary, several viral vectors have been successfully used for vaccine production and gene therapy. These vaccines can potentially induce a strong immune response in tissues and cells and achieve targeted delivery. Early-phase trials have shown that they are well tolerated in humans. Although the additional challenges lie ahead, the prospect of viral vector vaccine looks promising. Viral vectors are promising tools for the development of novel vaccines and vaccination approaches. Viral vector-based vaccines present advantages over traditional vaccines in that they can enhance a broad range of immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. https://www.creative-biolabs.com/vaccine/viral-vector-vaccine-design.htm
